PTC
18.10.2018 12:02:07 CEST | Business Wire | Press release
PTC (NASDAQ: PTC) today announced from Augmented World Expo (AWE) Europe 2018 the availability of new research in conjunction with Aberdeen Group titled, “How the Best-in-Class Use Augmented Reality for Superior Service Management.” The comprehensive research study and corresponding report identifies significant financial improvements realized by industrial companies embracing augmented reality (AR), and provides best practices for unlocking the potential of the technology across various environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181018005051/en/
In addition to the report published today, PTC announced exclusive data from Aberdeen that shows that organizations using AR have experienced significant year-over-year business growth and have improved their bottom lines dramatically.
“The rapid pace of the global market, digital transformation, and increasing shortage of highly skilled workers have produced a disruptive threat for businesses,” said Tom Paquin, research analyst, Aberdeen Group. “However, as evidenced by our latest report with PTC, companies that invest in AR, particularly manufacturing and service organizations, have the opportunity to gain a competitive advantage.”
For enterprises, AR can empower workers to understand and interact with the physical and digital worlds, build new skills with reduced training time and cost, and make informed decisions faster. As a result, businesses can unlock increased productivity and improve the effectiveness of training, manufacturing, and service.
“AR is one of the fastest growing segments in the technology market and has been shown to create significant business value for organizations adopting it. Industrial enterprises are keen to improve customer experiences, open up new revenue streams, and disrupt competition by leveraging the new AR capabilities for product and service differentiation,” said Jim Heppelmann, president and CEO, PTC. “Use cases being developed for end customers have a strong focus on service or maintenance instructions, enabling them to reduce machine downtime and maximize product value.”
AWE Europe 2018
PTC and the topic of enterprise AR took
center stage today at AWE Europe 2018, the world’s leading AR and VR
conference and expo, held October 18-19 in Munich, Germany.
This morning, Mike Campbell, EVP, Augmented Reality Products, PTC, led a keynote session titled, “PTC Vision for Augmented Reality in the Enterprise ,” in which he spoke about the state of AR in the industrial enterprise, reviewed customer use cases, and illustrated the power of AR to fundamentally change the way people work and to allow organizations to re-imagine how to manufacture, sell, operate, and service industrial products.
“Augmented reality can deliver a significant advantage for industrial organizations as part of their overall digital transformation,” said Mr. Campbell. “PTC customers are better leveraging existing investments in CAD, IoT, and digitalization of content through AR experiences, enabling people to visualize and interact with the digital world in the real-time context of their daily work.”
As a Titanium Sponsor of and exhibitor at the event, PTC is showcasing its latest AR solutions – Vuforia Studio, Vuforia Engine, and Vuforia Chalk – as well as distributing copies of the Aberdeen research report at booth 118. PTC is also participating in The International Symposium on Mixed and Augmented Reality (ISMAR) , which runs in conjunction with AWE Europe, in booth 405.
Adoption Under the Vuforia Brand
In line with the data and
findings of the Aberdeen report, PTC has experienced substantial growth
and adoption across its dedicated AR business unit. Over 60,000
commercial AR apps have been deployed with PTC’s Vuforia®
Engine. In addition, more than 14,000 participants have joined PTC’s
Vuforia Studio Free Trial program
, providing valuable feedback on
use case priorities and hardware requirements, and over 550,000
registered developers use Vuforia as their preferred platform to create
AR apps.
PTC has leveraged Vuforia to expand the capabilities of its market-leading ThingWorx ® Industrial Innovation Platform, enabling customers to visualize, instruct, guide, and improve interactions with physical things. Aberdeen data released today shows that Internet of Things (IoT) technology is currently a function of 82 percent of all businesses leveraging AR.
Aberdeen Report: “How the Best-in-Class Use Augmented Reality for
Superior Service Management”
The Aberdeen report, which
investigates service AR use cases of best-in-class organizations versus
all other adopters, offers the following highlights:
- Service organizations using AR have performed significantly better than non-users across customer retention, customer satisfaction, and year-over-year revenue improvement
- The best-in-class companies have performed, on average, 25 percent better than their peers across performance measurements, including regulatory and SLA compliance
- 34 percent of best-in-class organizations leverage AR-powered training, 31 percent use on-site guides, and 25 percent are using AR-powered knowledge sharing
To download a copy of the full report, please visit https://www.ptc.com/en/AWE-Europe .
Additional Resources
- Download the Aberdeen Report
- PTC Augmented Reality
- The State of Industrial Augmented Reality
- Harvard Business Review: “Why Every Organization Needs an AR Strategy,” authored by PTC CEO Jim Heppelmann and Harvard Professor Michael Porter
The adoption by customers of Vuforia AR solutions to date is not indicative of the amount of revenue with respect to any particular period or that customers will continue to adopt or deploy such technologies at any particular rate.
About PTC (NASDAQ: PTC)
PTC helps companies around the world
reinvent the way they design, manufacture, operate, and service products
in and for a smart, connected world. In 1986 we revolutionized digital
3D design, and in 1998 were first to market with Internet-based product
lifecycle management. Today, our leading industrial innovation platform
and field-proven solutions enable you to unlock value at the convergence
of the physical and digital worlds. With PTC, manufacturers and an
ecosystem of partners and developers can capitalize on the promise of
the Internet of Things and augmented reality technology today and drive
the future of innovation.
PTC, Vuforia, ThingWorx, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005051/en/
Contact:
PTC Jack McAvoy, 781-370-6143 Corporate Communications jmcavoy@ptc.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom